Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6271 to 6285 of 8901 results

  1. What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond to PPIs or H 2   receptor antagonists (H 2 RAs) despite optimum primary care?

    Recommendation ID CG184/5 Question What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in

    Research recommendation
    Published
    15 November 2019

  2. What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    Recommendation ID CG184/4 Question What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum

    Research recommendation
    Published
    15 November 2019

  3. Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical of UK clinical practice would be useful to determine the size of the effect of mifamurtide.

    Recommendation ID TA235/1 Question Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical

    Research recommendation
    Published
    9 June 2015

  4. Behavioural strategies and programmes:- What is the feasibility and effectiveness of specific behavioural strategies and programmes to reduce inappropriate antimicrobial demand and use and to prevent infections occurring and spreading?

    Recommendation ID NG63/2 Question Behavioural strategies and programmes:- What is the feasibility and effectiveness of specific behavioural

    Research recommendation
    Published
    17 February 2017

  5. High-risk groups:- What interventions to prevent infection and reduce antimicrobial resistance are effective for groups of people at high risk of infection? This includes people who:- have suppressed immune systems (for example, because of HIV, an inherited condition or treatment they may be having for conditions such as cancer or an organ transplant)- have a chronic disease- live in crowded conditions (see Shelter's definition)- are homeless- have been in prison- have migrated from countries with a high prevalence of infectious diseases such as tuberculosis (examples include South Asia and sub-Saharan Africa).

    Recommendation ID NG63/3 Question High-risk groups:- What interventions to prevent infection and reduce antimicrobial resistance are effective

    Research recommendation
    Published
    17 February 2017

  6. Cost effectiveness:- What is the cost effectiveness of interventions to prevent infection and promote the appropriate use of antimicrobials?

    Recommendation ID NG63/1 Question Cost effectiveness:- What is the cost effectiveness of interventions to prevent infection and promote

    Research recommendation
    Published
    17 February 2017

  7. Older people in day and residential care:- How effective are interventions in day and residential care for older people that aim to prevent infection and to reduce antimicrobial resistance?

    Recommendation ID NG63/5 Question Older people in day and residential care:- How effective are interventions in day and residential care

    Research recommendation
    Published
    17 February 2017

  8. Workplace:- How effective are interventions in the workplace that aim to prevent infection and reduce antimicrobial resistance?

    Recommendation ID NG63/4 Question Workplace:- How effective are interventions in the workplace that aim to prevent infection and reduce

    Research recommendation
    Published
    17 February 2017

  9. Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification when selecting which people with CUADT would benefit from short- or long-term enteral nutrition?

    Recommendation ID NG36/4 Question Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification

    Research recommendation
    Published
    6 April 2016

  10. Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and pathological factors?

    Recommendation ID NG36/3 Question Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary

    Research recommendation
    Published
    6 April 2016

  11. Systemic imaging – who and why?:- What factors determine the risk of a person presenting with CUADT having metastasis or a second primary cancer?

    Recommendation ID NG36/1 Question Systemic imaging – who and why?:- What factors determine the risk of a person presenting with CUADT having

    Research recommendation
    Published
    6 April 2016

  12. Follow-up:- What is the optimal method, frequency and duration of follow-up for people who are disease-free after treatment for CUADT?

    Recommendation ID NG36/5 Question Follow-up:- What is the optimal method, frequency and duration of follow-up for people who are disease-free

    Research recommendation
    Published
    6 April 2016

  13. HPV testing:- What is the comparative effectiveness of single-step laboratory diagnostic tests to identify human papillomavirus (HPV) against current diagnostic test algorithms and reference standards in people with cancer of the oropharynx?

    Recommendation ID NG36/2 Question HPV testing:- What is the comparative effectiveness of single-step laboratory diagnostic tests to identify

    Research recommendation
    Published
    6 April 2016

  14. The committee also noted that the additional evidence exploring the relationship between radiological measures of bone defects (that is, the Rickets Severity Score and the Radiographic Global Impression of Change) and health-related quality of life would help to address several key uncertainties in the economic analysis.

    Recommendation ID HST8/2 Question The committee also noted that the additional evidence exploring the relationship between radiological

    Research recommendation
    Published
    22 March 2019

  15. Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or without LTRA:- What is the clinical and cost effectiveness of offering additional maintenance therapy to adults, young people and children with asthma that is uncontrolled on a moderate dose of ICS plus LABA with or without LTRA?

    Recommendation ID NG80/8 Question Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or without

    Research recommendation
    Published
    18 October 2018